AUTHORS
Krista Anne Goerger, BSc, Livia Stanger, PhD2, Ashleigh Kilgore3, Andrew Rickenberg4, Adriana Yamaguchi5, Mariane Flores Nascimento, PhD6, Bertram Pitt7, Y. Eugene Eugene Chen8, Michael Holinstat, PhD9
AFFILIATIONS
1 University of Michigan Medical Center, Ann Arbor, Michigan, United States
2 University of Michigan Medical Center, Ann Arbor, Michigan, United States
3 University of Michigan Medical Center, Ann Arbor, Michigan, United States
4 University of Michigan Medical Center, Ann Arbor, Michigan, United States
5 University of Michigan Medical Center, Ann Arbor, Michigan, United States
6 University of Michigan Medical Center, Ann Arbor, Michigan, United States
7 University of Michigan Medical Center, Ann Arbor, Michigan, United States
8 University of Michigan Medical Center, Ann Arbor, Michigan, United States
9 University of Michigan Medical Center, Ann Arbor, Michigan, United States, University of Michigan Medical Center, Ann Arbor, Michigan, United States
ABSTRACT
The increasing prevalence of type 2 diabetes mellitus (T2DM) has been accompanied by a parallel rise in cardiovascular disease, which remains the leading cause of morbidity and mortality in this population. While sodium-glucose cotransporter (SGLT) inhibitors have transformed the management of T2DM through improvements in glycemic control. Additionally, sotagliflozin, the first FDA-approved dual SGLT1/SGLT2 inhibitor, has demonstrated significant reductions in myocardial infarction and stroke among patients with T2DM at high cardiovascular risk in secondary analysis of the SCORED trial, suggesting potential mechanisms.
To investigate whether modulation of platelet function contributes to the cardiovascular protection associated with sotagliflozin, we compared the effects of sotagliflozin and the selective SGLT2 inhibitor empagliflozin on platelet activation and thrombus formation. Using ex vivo studies with blood from healthy donors and patients with T2DM, we found that sotagliflozin significantly inhibited platelet integrin activation, granule secretion, aggregation, and ex vivo thrombus formation. In contrast, empagliflozin produced minimal or no measurable effects on platelet function. Consistent with these findings, sotagliflozin reduced thrombus formation in the in vivo murine thrombosis model while preserving normal hemostatic function. Mechanistically, sotagliflozin inhibited glucose uptake in platelets, suggesting a previously unrecognized role for SGLT-mediated glucose transport in regulating platelet activation. Interestingly, phlorizin, another dual SGLT1/SGLT2 inhibitor, did not reproduce the antiplatelet effects of sotagliflozin, indicating that inhibition of glucose transport alone may not fully explain the observed effects and suggesting additional mechanisms contribute to platelet regulation.
To translate these findings to humans, we conducted a randomized crossover clinical study in 20 healthy volunteers. Participants received aspirin (81 mg once daily), clopidogrel (75 mg once daily), apixaban (5 mg twice daily), or sotagliflozin (400 mg once daily) for two weeks, followed by a two-week washout period before crossing over to the next treatment arm. Blood samples were collected before and after each treatment period to evaluate platelet activation and coagulation parameters. As expected, aspirin and clopidogrel significantly inhibited platelet activation, whereas apixaban altered coagulation parameters measured by thromboelastography. In contrast, short-term administration of sotagliflozin did not significantly alter platelet activation in healthy volunteers despite the robust antiplatelet effects observed in our ex vivo studies. These findings suggest that factors such as circulating drug concentrations, treatment duration, or disease-specific platelet phenotypes may influence the ability of sotagliflozin to modulate platelet function in vivo. Given that patients with T2DM exhibit heightened platelet reactivity and represent the population in which reductions in myocardial infarction and stroke have been demonstrated clinically in the SCORED trial, future studies are needed to determine whether the antiplatelet effects of sotagliflozin are more pronounced in these higher-risk populations.
Collectively, these studies identify sotagliflozin as a novel regulator of platelet function and thrombosis and provide evidence that dual SGLT1/SGLT2 inhibition exerts biological effects distinct from selective SGLT2 inhibition. These findings establish a foundation for future investigations into the role of platelet SGLTs in thrombotic disease and provide a potential mechanistic framework linking sotagliflozin treatment to the reduction in ischemic cardiovascular events observed in clinical trials.
DISCLOSURES
Krista Anne Goerger, BSc: No relevant conflicts of interest to declare.